Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.92Last Year’s EPS
0.07Same Quarter Last Year
Strong Buy
Based on 23 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -21.45%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.Company Guidance
During the call, Sarepta Therapeutics updated its guidance for the year, projecting net product revenue between $2.3 billion and $2.6 billion across its four approved therapies. This adjustment reflects several factors, including a significant safety event involving their gene therapy product ELEVIDYS, which contributed to delays in patient treatment. The company reported first-quarter total net product revenue of $612 million, marking a 70% increase compared to the previous year, with ELEVIDYS achieving sales of $375 million, a 180% increase. While the PMO franchise grew by 5% to $237 million, the company anticipates a 20% revenue decrease in Q2 compared to Q1 due to ongoing impacts from the safety event and administrative challenges. Sarepta emphasized its commitment to improving patient access and education while addressing site capacity issues to support revenue growth for the remainder of 2025.Strong Revenue Growth
Sarepta achieved $612 million in total net product revenue for the first quarter of 2025, representing 70% growth over the same quarter last year.
ELEVIDYS Sales Increase
ELEVIDYS achieved sales of $375 million in the quarter, representing a 180% increase over the same quarter last year.
Successful PMO Franchise Growth
The PMO franchise grew 5%, achieving $237 million for the quarter.
Positive Long-Term Demand Outlook
Despite short-term challenges, Sarepta projects a pickup in demand beginning in the summer and extending through the remainder of the year, maintaining confidence in the long-term demand outlook for ELEVIDYS.
---
SRPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $46.75 | $36.72 | -21.45% |
| Feb 26, 2025 | $106.86 | $103.06 | -3.56% |
| Nov 06, 2024 | $127.97 | $120.42 | -5.90% |
| Aug 07, 2024 | $140.06 | $136.40 | -2.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sarepta Therapeutics (SRPT) report earnings?
Sarepta Therapeutics (SRPT) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Sarepta Therapeutics (SRPT) earnings time?
Sarepta Therapeutics (SRPT) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRPT EPS forecast?
SRPT EPS forecast for the fiscal quarter 2025 (Q2) is 0.92.
---
